Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01721057 · ClinicalTrials.gov registry record · Phase 3
A Study in Moderate to Severe Rheumatoid Arthritis Participants
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 684
- Enrollment target
NCT01721057 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 684 participants.
The verdict
NCT01721057, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 684 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily (QD) is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had inadequate response to or are intolerant to at least 1 conventional disease-modifying antirheumatic drug (cDMARD)(cDMARD-IR \[inadequate response\] participants) and who have not received a biologic disease-modifying antirheumatic drug (DMARD).
Interventions
- DRUG Placebo
- DRUG Baricitinib
- DRUG cDMARD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 684 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01721057
The ClinicalTrials.gov registry entry for NCT01721057 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 684 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01721057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01721057 about?
NCT01721057 is a clinical study titled "A Study in Moderate to Severe Rheumatoid Arthritis Participants". The purpose of this study is to determine whether baricitinib 4 milligram (mg) once daily (QD) is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had inadequate response to or are intolerant to at least 1 conventional disease...
What is the current status of trial NCT01721057?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 684 participants. The study started on 2012-12. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01721057?
The interventions under investigation include: Placebo (DRUG), Baricitinib (DRUG), cDMARD (DRUG).
Who is sponsoring clinical trial NCT01721057?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.